Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.